Bruker Corporation (BRKR) Stock Analysis
Market Closed
Sector: Technology · Industry: Laboratory Analytical Instruments
What's happening with BRKR
Price History
5-Year Weekly Candlestick Chart
Profile
profitability, growth, valuation and financial health lag behind.
How is each axis scored?
- Valuation35/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (0.5%)5/25
- P/S (2.7x)20/25
- EV/EBIT (234.3x)0/25
- Growth20/100 · Weak
- Revenue CAGR (14.7%)20/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability10/100 · Weak
- ROIC (0.9%)5/25
- ROE (-0.5%)0/25
- Net margin (-0.3%)0/25
- Operating margin (1.3%)5/25
- Financial Health43/100 · Weak
- Altman Z (1.83)10/25
- Current ratio (1.55)18/25
- Interest coverage (1.8x)3/25
- Net cash / debt (D/A 25%)12/25
- Quality55/100 · Moderate
- Piotroski F (4/9)10/25
- Beneish M (-2.44)20/25
- FCF conversion (-442%)0/25
- Margin stability (σ 4.8%)25/25
About Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. Show more
The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
Headquarters: BILLERICA, MA · Employees: 11,085 · Website ↗
Analyst Consensus
BuyWall Street consensus estimates — not a PMP forecast · Updated Sep 21, 2026
Insider Transactions
Recent SEC Form 4 filings
- SellTax withholding · filed 2026-08-13-1619 sh2026-08-11
- SellTax withholding · filed 2026-08-13-1410 sh2026-08-11
- SellTax withholding · filed 2026-08-13-4838 sh2026-08-11
- SellTax withholding · filed 2026-08-11-1573 sh2026-08-10
- SellTax withholding · filed 2026-08-11-1289 sh2026-08-10
+3 more recent filings
Key Metrics
Financial snapshot — pillar inputs plus per-share and market context
Valuation
35DP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF42.2xC
Grade C: Exp.Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield0.5%C
Grade C: LowTTM FCF / Market Cap — vs own 5Y history: -0.2%–2.7% · 11th pct
P/S (TTM)2.71xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 1.3x–5.7x · 33rd pct
EV/EBIT234.3xD
Grade D: Exp.Enterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 19.1x–243.8x · highest in history
EV/Sales3.2xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E28.0xC
Grade C: Exp.Price / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio3.80xC
Grade C: Exp.Price to Book Value. Neg. equity = heavy buybacks
PEG Ratio1.92B
Grade B: FairFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield0.58%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio26.7%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
10EROIC0.9%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-0.5%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-1.1%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-0.3%D
Grade D: LowNet Income / Revenue
Operating Margin1.3%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin45.3%C
Grade C: AvgGross Profit / Revenue
FCF Margin1.5%D
Grade D: LowFCF / Revenue
True FCF Margin0.9%D
Grade D: LowTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Financial Health
43D+Altman Z-Score1.83C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.55xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio0.85xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage1.8xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment30.0yD
Grade D: SlowYears to repay net debt via FCF
Net Debt/EBIT33.0xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity0.68xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.08xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Growth
20ERevenue CAGR14.7%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Forward Growth—
Implied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)-0.3%B
Grade B: FlatShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue0.6%A
Grade A: LowTTM stock-based comp / TTM Revenue
Quality
1/9 Loss Years55CPiotroski F-Score4/9C
Grade C: AvgFinancial strength 0–9. >7 Strong
Beneish M-Score-2.44A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion-442.2%D
Grade D: PoorFCF / Net Income
Margin Stability4.8%A
Grade A: StableEBIT margin std deviation. Lower = stable
Capex / Revenue2.6%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.55xC
Grade C: AvgRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$1.96
Cash & short-term investments per share (Finnhub)
Book Value / Share$16.15
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$1.67B
Total debt obligations (short + long term)
Cash & Equiv.$133.40M
Cash and short-term investments
Net Debt$1.54B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$2.47B
Shareholders' equity (book value)
Asset / Liability1.67xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$9.38B
Current Market Capitalization
Beta1.25C
Grade C: VolatilePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
S hraničným Altmanovým skóre 1,83, 30-ročnou dobou splácania dlhu a zanedbateľným FCF výnosom 0,5 % je BRKR vysoko rizikovou a predraženou investíciou s minimálnym generovaním hotovosti.
Takes ~30.0 years to repay net debt from free cash flow.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Mar 2026 · Ratio snapshot Sep 22, 2026
Key Insights: Bruker Corporation (BRKR)
Composite verdict for Bruker Corporation: S hraničným Altmanovým skóre 1,83, 30-ročnou dobou splácania dlhu a zanedbateľným FCF výnosom 0,5 % je BRKR vysoko rizikovou a predraženou investíciou s minimálnym generovaním hotovosti.. Piotroski F-Score of 4/9 indicates mixed fundamentals for Bruker Corporation. Altman Z-Score of 1.83 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out. Beneish M-Score of -2.44 suggests a low likelihood of earnings manipulation.
- Takes ~30.0 years to repay net debt from free cash flow.
- Interest coverage of 1.8× leaves little room for earnings shocks.
- Bruker Corporation posted a net loss in 1 of 9 available completed fiscal years (2016–2025).
See how BRKR ranks on the Capex Tracker — top 50 capital spenders compared.
No significant market moves for BRKR in the last 30 days.
See BRKR move history →Frequently Asked Questions about BRKR
Is BRKR stock a buy right now?
PreMarketPrice's quantitative model rates Bruker Corporation's financial health at 43/100 — S hraničným Altmanovým skóre 1,83, 30-ročnou dobou splácania dlhu a zanedbateľným FCF výnosom 0,5 % je BRKR vysoko rizikovou a predraženou investíciou s minimálnym generovaním hotovosti.. This is a data-driven snapshot of fundamentals, not investment advice.
Is BRKR stock overvalued?
Bruker Corporation trades at a trailing P/E of n/a and our valuation score rates it 35/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Bruker Corporation report earnings?
No confirmed earnings date is currently scheduled for BRKR. The Earnings section lists recent reports and updates as dates are announced.
What sector does Bruker Corporation operate in?
Bruker Corporation operates in the Technology sector, within the Laboratory Analytical Instruments industry. The Related Stocks section lists sector peers for comparison.
What does Bruker Corporation do?
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries.
About Bruker Corporation (BRKR) Stock
Bruker Corporation (BRKR) is a US-listed stock operating in the Technology sector, specifically the Laboratory Analytical Instruments industry. Real-time pricing data for Bruker Corporation is available on this page with a market capitalization of $9.4 billion. The financial health score for BRKR is 43/100, which indicates weak financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for BRKR stock.
BRKR Stock Analysis & Key Metrics
On PreMarketPrice, you can track Bruker Corporation (BRKR) across multiple dimensions:
- Pre-market price & movement: Real-time BRKR stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for BRKR with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Bruker Corporation across multiple reporting periods.
- Financial health score: A composite score of 43/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for BRKR.
- Sector peers: Compare BRKR against 10 other technology stocks on key financial metrics.
Is BRKR a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Bruker Corporation (BRKR) as an investment. The financial health score of 43/100 suggests weak financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Bruker Corporation (BRKR) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.